Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All ivermectin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19ivm.org COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Error in the Exclusion of Participants From Analysis in the ACTIV-6 Platform Randomized Clinical Trial

Naggie, S., JAMA, doi:10.1001/jama.2024.8723
May 2024  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020
 
*, now with p < 0.00000000001 from 105 studies, recognized in 23 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,800+ studies for 95 treatments. c19ivm.org
Partial correction to ACTIV-6 600 confirming that 16% of patients were missing in the analysis.
It's not clear how the trial could have such a large error for the number of patients randomized, why the correction took over a year, or why the many other errors have not been corrected1.
The revised data exhibits additional concerns:
138 did not receive the study medication in the first version while only 27 did not receive it in the second version.
8.0% of the original patients reported had an adverse event while only 0.4% of the newly added patients did (eTable 2).
2.4% of the original patients had missing symptom severity while 32% of the newly added patients did (eFigure 4).
3 patients had missing symptom onset dates in the original set, while none are reported for the larger set (eFigure 4).
There are many anomolies in the CONSORT diagrams. Although both start with the same initial number of patients assessed:
10 had a drug allergy to ivermectin in the first version while only 7 do in the second version.
11 were on warfarin in the first version while only 4 were in the second version.
9 were hospitalized in the last 10 days in the first version while only one was in the second version.
7 had current use of ivermectin in the first version while only 4 had current or recent use in the second version.
The second version claims 78 were exluded for symptom onset >7 days which is not in the first version, and both versions show patients up to 10 days from onset included (eFigure 2).
In the second version, 17 fewer patients were eligible but elected not to continue.
There are many more anomalies in the CONSORT diagrams.
For many additional errors and concerns see1.
Naggie et al., 16 May 2024, peer-reviewed, 1 author.
This PaperIvermectinAll
{ 'indexed': {'date-parts': [[2024, 5, 17]], 'date-time': '2024-05-17T00:36:05Z', 'timestamp': 1715906165438}, 'reference-count': 2, 'publisher': 'American Medical Association (AMA)', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'DOI': '10.1001/jama.2024.8723', 'type': 'journal-article', 'created': {'date-parts': [[2024, 5, 16]], 'date-time': '2024-05-16T19:30:35Z', 'timestamp': 1715887835000}, 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Error in the Exclusion of Participants From Analysis in the ACTIV-6 Platform Randomized Clinical ' 'Trial', 'prefix': '10.1001', 'author': [ { 'given': 'Susanna', 'family': 'Naggie', 'sequence': 'first', 'affiliation': [ { 'name': 'Duke Clinical Research Institute, Duke University School of ' 'Medicine, Durham, North Carolina'}]}], 'member': '10', 'published-online': {'date-parts': [[2024, 5, 16]]}, 'reference': [ { 'issue': '11', 'key': 'jle240062r1', 'doi-asserted-by': 'publisher', 'first-page': '888', 'DOI': '10.1001/jama.2023.1650', 'article-title': 'Effect of higher-dose ivermectin for 6 days vs placebo on time to ' 'sustained recovery in outpatients with COVID-19: a randomized clinical ' 'trial.', 'volume': '329', 'author': 'Naggie', 'year': '2023', 'journal-title': 'JAMA'}, { 'key': 'jle240062r2', 'article-title': 'Errors in results from erroneous exclusion of participants in analysis.', 'journal-title': 'JAMA'}], 'container-title': 'JAMA', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://jamanetwork.com/journals/jama/articlepdf/2818991/jama_naggie_2024_le_240062_1715708612.16601.pdf', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2024, 5, 16]], 'date-time': '2024-05-16T19:30:37Z', 'timestamp': 1715887837000}, 'score': 1, 'resource': {'primary': {'URL': 'https://jamanetwork.com/journals/jama/fullarticle/2818991'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2024, 5, 16]]}, 'references-count': 2, 'URL': 'http://dx.doi.org/10.1001/jama.2024.8723', 'relation': {}, 'ISSN': ['0098-7484'], 'subject': [], 'container-title-short': 'JAMA', 'published': {'date-parts': [[2024, 5, 16]]}}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit